RYTM RHYTHM PHARMACEUTICALS, INC.
8-K Current Report
Filed: March 2, 2026
Health Care
Pharmaceutical PreparationsRHYTHM PHARMACEUTICALS, INC. (RYTM) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 7.01 · Regulation FD Disclosure
- • Exhibit 99.1 contains the actual disclosed material; investor-relevant content resides there, not in the boilerplate item text
- • Reg FD filing signals Rhythm Pharmaceuticals shared material non-public information publicly, likely a clinical update, partnership, or business development event worth monitoring
Item 8.01 · Other Events
- • Setmelanotide hit primary endpoint in 142-patient TRANSCEND trial: -16.4% BMI reduction vs +2.4% for placebo at 52 weeks (p<0.0001)
- • Placebo-adjusted BMI reduction of -18.8%, a clinically meaningful delta supporting drug efficacy in hypothalamic obesity
Other RHYTHM PHARMACEUTICALS, INC. 8-K Filings
Get deeper insights on RHYTHM PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.